Bilaketaren emaitzak - David D. Stenehjem

  • Erakusten 1 - 8 emaitzak -- 8
Findu emaitzak
  1. 1
    Panobinostat for the treatment of multiple myeloma: the evidence to date

    Panobinostat for the treatment of multiple myeloma: the evidence to date nork Sunil Sharma, Hanna Bailey, David D. Stenehjem

    Argitaratua 2015
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  2. 2
    PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer

    PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer nork David D. Stenehjem, Dao Tran, Michael Nkrumah, Shilpa Gupta

    Argitaratua 2018
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  3. 3
    Tumor mutational burden in lung cancer: a systematic literature review

    Tumor mutational burden in lung cancer: a systematic literature review nork Connor Willis, Michelle Fiander, Dao Tran, Beata Korytowsky, John-Michael Thomas, Florencio Calderon, Teresa Zyczynski, Diana Brixner, David D. Stenehjem

    Argitaratua 2019
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  4. 4
    Cancer incidence in immunocompromised patients: a single-center cohort study

    Cancer incidence in immunocompromised patients: a single-center cohort study nork Sabrina Ilham, Connor Willis, Kibum Kim, Karen Chung, Brenda Wood, Malinda S. Tan, Chia Jie Tan, Danielle Nguyen, Diana Brixner, David D. Stenehjem

    Argitaratua 2023
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  5. 5
    Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer

    Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer nork David Waterhouse, Jenny Lam, Keith A. Betts, Lei Yin, Sophie Gao, Yong Yuan, John Hartman, Sumati Rao, Solomon J. Lubinga, David D. Stenehjem

    Argitaratua 2021
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  6. 6
    Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma

    Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma nork James A. Kuzman, David D. Stenehjem, Joseph A. Merriman, Archana M. Agarwal, Shiven B. Patel, Andrew W. Hahn, Anitha Alex, Dan Albertson, David Gill, Neeraj Agarwal

    Argitaratua 2017
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  7. 7
    Circulating immune cell phenotype dynamics reflect the strength of tumor–immune cell interactions in patients during immunotherapy

    Circulating immune cell phenotype dynamics reflect the strength of tumor–immune cell interactions in patients during immunotherapy nork Jason I. Griffiths, Pierre Wallet, Lance Pflieger, David D. Stenehjem, Xuan Liu, Patrick A. Cosgrove, Neena A. Leggett, Jasmine A. McQuerry, Gajendra Shrestha, Maura Rossetti, Gemalene Sunga, Philip J. Moos, Frederick R. Adler, Jeffrey T. Chang, Sunil Sharma, Andrea H. Bild

    Argitaratua 2020
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  8. 8
    American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer

    American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer nork Gary H. Lyman, Marc Carrier, Cihan Ay, Marcello Di Nisio, Lisa K. Hicks, Alok A. Khorana, Andrew D. Leavitt, Agnes Y.Y. Lee, Fergus Macbeth, Rebecca L. Morgan, Simon Noble, Elizabeth A. Sexton, David D. Stenehjem, Wojtek Wiercioch, Lara A Kahale, Pablo Alonso‐Coello

    Argitaratua 2021
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:

Bilaketa egiteko lanabesak: